These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36333093)

  • 1. Molecular and clinical characterization of H3 K27M-mutant "non-midline" glioblastoma: A case report and literature review.
    Onishi S; Ohba S; Kuraoka K; Kurashige T; Sugiyama K; Yamasaki F
    Neurocirugia (Astur : Engl Ed); 2022; 33(6):356-360. PubMed ID: 36333093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
    Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
    Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
    Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
    Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tectal Low-Grade Glioma with H3 K27M Mutation.
    Sumi K; Shijo K; Igarashi T; Yamamuro S; Sasano M; Oshima H; Ishige T; Honma T; Yagasaki H; Yoshino A
    World Neurosurg; 2020 Sep; 141():91-100. PubMed ID: 32505657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An adult case of diffuse midline glioma with H3 K27M mutation.
    Tu JH; Piao YS; Lu DH; Wang LM; Liu L; Bai DY; Han HW; Lin YK; Zhong S
    Neuropathology; 2020 Dec; 40(6):627-631. PubMed ID: 32954563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic profiling and prognostic factors of H3 K27M-mutant spinal cord diffuse glioma.
    Chai RC; Yan H; An SY; Pang B; Chen HY; Mu QH; Zhang KN; Zhang YW; Liu YQ; Liu X; Zhao Z; Jiang T; Wang YZ; Jia WQ
    Brain Pathol; 2023 Jul; 33(4):e13153. PubMed ID: 36751054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
    Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M
    J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of H3 K27M-mutant gliomas in adults.
    Meyronet D; Esteban-Mader M; Bonnet C; Joly MO; Uro-Coste E; Amiel-Benouaich A; Forest F; Rousselot-Denis C; Burel-Vandenbos F; Bourg V; Guyotat J; Fenouil T; Jouvet A; Honnorat J; Ducray F
    Neuro Oncol; 2017 Aug; 19(8):1127-1134. PubMed ID: 28201752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive assessment of H3 K27M mutational status in diffuse midline gliomas by using apparent diffusion coefficient measurements.
    Chen H; Hu W; He H; Yang Y; Wen G; Lv X
    Eur J Radiol; 2019 May; 114():152-159. PubMed ID: 31005167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffusion Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3-K27M Mutation Using Apparent Diffusion Coefficient Histogram Analysis.
    Aboian MS; Tong E; Solomon DA; Kline C; Gautam A; Vardapetyan A; Tamrazi B; Li Y; Jordan CD; Felton E; Weinberg B; Braunstein S; Mueller S; Cha S
    AJNR Am J Neuroradiol; 2019 Nov; 40(11):1804-1810. PubMed ID: 31694820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
    Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
    J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. H3 K27M-mutant diffuse midline gliomas in different anatomical locations.
    Wang L; Li Z; Zhang M; Piao Y; Chen L; Liang H; Wei Y; Hu Z; Zhao L; Teng L; Lu D
    Hum Pathol; 2018 Aug; 78():89-96. PubMed ID: 29727696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma.
    Pagès M; Beccaria K; Boddaert N; Saffroy R; Besnard A; Castel D; Fina F; Barets D; Barret E; Lacroix L; Bielle F; Andreiuolo F; Tauziède-Espariat A; Figarella-Branger D; Puget S; Grill J; Chrétien F; Varlet P
    Brain Pathol; 2018 Jan; 28(1):103-111. PubMed ID: 27984673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
    Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
    Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of diffuse midline glioma, H3 K27M mutant mimicking a hemispheric malignant glioma in an elderly patient.
    Fujioka Y; Hata N; Hatae R; Suzuki SO; Sangatsuda Y; Nakahara Y; Mizoguchi M; Iihara K
    Neuropathology; 2020 Feb; 40(1):99-103. PubMed ID: 31762138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone H3 K27M mutations in adult cerebellar high-grade gliomas.
    Nakata S; Nobusawa S; Yamazaki T; Osawa T; Horiguchi K; Hashiba Y; Yaoita H; Matsumura N; Ikota H; Hirato J; Yoshimoto Y; Yokoo H
    Brain Tumor Pathol; 2017 Jul; 34(3):113-119. PubMed ID: 28547652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.
    López-Pérez CA; Franco-Mojica X; Villanueva-Gaona R; Díaz-Alba A; Rodríguez-Florido MA; Navarro VG
    J Neurooncol; 2022 Jul; 158(3):369-378. PubMed ID: 35567713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation.
    Aboian MS; Solomon DA; Felton E; Mabray MC; Villanueva-Meyer JE; Mueller S; Cha S
    AJNR Am J Neuroradiol; 2017 Apr; 38(4):795-800. PubMed ID: 28183840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman.
    Low JT; Wang SH; B Peters K
    CNS Oncol; 2021 Jun; 10(2):CNS71. PubMed ID: 33908265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A longitudinally extensive H3 K27M-mutant diffuse midline glioma in an elderly patient clinically mimicking central nervous system inflammation: a case report.
    Babarczy K; Reisz Z; Szabo E; Rajda C; Vecsei L; Bodi I; Klivenyi P; Hortobagyi T; Szalardy L
    Folia Neuropathol; 2020; 58(4):377-385. PubMed ID: 33480242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.